论文部分内容阅读
目的探讨清蛋白结合型紫杉醇治疗晚期复治乳腺癌的临床疗效。方法选取江油市人民医院2012—2015年收治的118例晚期复治乳腺癌患者,随机分为试验组与参照组,各59例,试验组患者给予清蛋白结合型紫杉醇治疗,参照组患者给予诺维本治疗,观察两组患者临床疗效、存活情况、毒副作用发生情况。结果试验组患者总有效率、存活率高于参照组,差异有统计学意义(P<0.05)。两组患者外周神经症状、脱发、骨髓抑制、恶心呕吐发生率比较,差异无统计学意义(P>0.05)。结论清蛋白结合型紫杉醇治疗晚期复治乳腺癌的临床疗效确切,毒副作用患者可耐受,无严重不良事件,可改善患者预后,提高患者生活质量。
Objective To investigate the clinical efficacy of albumin-bound paclitaxel in the treatment of advanced breast cancer. Methods A total of 118 patients with advanced breast cancer who were treated in Jiangyou People’s Hospital from 2012 to 2015 were randomly divided into trial group and reference group, 59 cases in each group. Patients in trial group were treated with albumin-bound paclitaxel, Weiben treatment, observation of two groups of patients clinical efficacy, survival, side effects. Results The total effective rate and survival rate of the experimental group were higher than that of the reference group, the difference was statistically significant (P <0.05). There was no significant difference between the two groups in the incidence of peripheral neurological symptoms, hair loss, bone marrow suppression and nausea and vomiting (P> 0.05). Conclusions The albumin-binding paclitaxel is effective in the treatment of advanced breast cancer. The patients with toxic and side effects can tolerate without serious adverse events, which can improve the prognosis and improve the quality of life of patients.